



PATENT
930008-2113

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Matthias FINCKH, Katalin TISA-BOSTEDT,
Eva FISCHBACHER

Serial No. : 10/680,956

For : TRANSDERMAL DRUG DELIVERY SYSTEM
FOR OXYBUTYNIN

Filed : October 8, 2003

Examiner : Not Yet Assigned

Art Unit : 1615

745 Fifth Avenue
New York, NY 10151

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 28, 2004.

Ronald R. Santucci, Reg. No. 28,988

Name of Applicant, Assignee or Registered Representative

June 28, 2004

Date of Signature

TRANSMITTAL OF CERTIFIED COPY OF PRIORITY DOCUMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Applicants enclose herewith a certified copy of German Patent Application No. 102 51 256.6 filed November 4, 2002 which has been claimed for priority benefits in the above referenced patent application.

PATENT
930008-2113

The Commissioner is authorized to charge any additional fees that may be required to
Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Ronald R. Santucci
Reg. No. 28,988
(212) 588-0800

BUNDESREPUBLIK DEUTSCHLAND



Prioritätsbescheinigung über die Einreichung einer Patentanmeldung

Aktenzeichen: 102 51 256.6

Anmeldetag: 4. November 2002

Anmelder/Inhaber: Novosis AG, Miesbach/DE

Bezeichnung: Oxybutynin TDS

IPC: A 61 L, A 31 K, A 61 K

Die angehefteten Stücke sind eine richtige und genaue Wiedergabe der ursprünglichen Unterlagen dieser Patentanmeldung.

München, den 27. Oktober 2003
Deutsches Patent- und Markenamt
Der Präsident
Im Auftrag



A handwritten signature in black ink, appearing to read "Schäfer", is written over a horizontal line. The line is part of a larger, stylized signature that includes a large, sweeping flourish extending from the left.

October 31, 2002

Our ref.: New German Patent Application
Novosis AG
Oxybutynin TDS

Transdermal drug delivery system for oxybutynin

WO 99/48 493 describes an oxybutynin patch obtained according to the socalled hot melt process. It is stated that the patch does not contain any enhancer. Nevertheless substances which are usually used as enhancers, are mentioned, especially citric acid triester.

US 5 601 839 describes triacetin as an agent improving permeability.

As regards oxybutynin patches, US 5 411 740 and WO 93/23 025 should also be mentioned.

The problem underlaying the invention is solved by a transdermal drug delivery system (TDS) comprising

- a cover which is impermeable for the active ingredient,
- a matrix containing oxybutynin as active ingredient and
- a facultative release liner, wherein the matrix further comprises
 - an Aloe Vera extract,
 - a pressure sensitive adhesive and
 - a cross linking agent for the adhesive.

The transdermal drug delivery system according to the invention may comprise racemic oxybutynin, R-oxybutynin, S-oxybutynin or desethyl-oxybutynin.

Further, the pressure sensitive adhesive of the transdermal drug delivery system according the invention may comprise or consist of an acrylate based polymer, preferably a polymer based on an acrylate-vinyl acetate copolymer.

Further, the pressure sensitive adhesive of the transdermal drug delivery system according to the invention may comprise or consist of Durotak 2287 or Durotak 2516.

Further, the matrix of the transdermal drug delivery system according to the invention may comprise Ti-acetylacetone, Al-acetylacetone or polybutyl-titanate as crosslinking agent.

Further the extracting agent of the Aloe Vera-extract of the transdermal drug delivery system according to the invention may be a vegetable oil, preferably soybean oil.

An Aloe Vera-extract is available from, for example, Caesar & Loretz (Hilden/Germany) .

Further, the Aloe Vera-extract of the transdermal drug delivery system according to the invention may comprise 5 to 15 % by weight of Aloe Vera oil and 95 to 85 % by weight of the vegetable oil.

Further, the matrix of the transdermal drug delivery system according to the invention may comprise the Aloe Vera-extract as the only enhancer.

Further, the matrix of the transdermal drug delivery system according to the invention may comprise 5 to 40, preferably 10 to 35 and especially 15 to 30 % by weight of oxybutynin (based on the matrix).

Further, the matrix of the transdermal drug delivery system according to the invention may comprise 10 to 25, preferably 12 to 20 and especially 14 to 18 % by weight of Aloe Vera-extract (based on the matrix).

Further, the matrix of the transdermal drug delivery system according to the invention may comprise 0.1 to 5.0, preferably 0.3 to 3 and especially 0.5 to 2.0 % by weight of the crosslinking agent (based on the matrix).

The transdermal drug delivery system according to the invention may have a surface of 5 to 80, preferably 10 to 60 and especially 20 to 50 cm².

Example and comparative example

A composition of a matrix according to the invention was provided as follows:

Oxybutynin	20.0 %
Aloe Vera-extract (soy bean oil)	15.0 %
Ti-acetylacetone (Tyzor AA 75)	1.3 %
Durotak 2287	remainder

This composition was subjected to a permeation test (mouse skin). The maximum flux was 9.2 µg/cm²/h. The permeation was 190 µg/cm²/24 h.

According to US 5 601 839 a matrix was provided with the following composition.

Oxybutynin	20.0 %
Triacetin	15.0 %
Al-Acetylacetone	0.5 %

Durotak 2051 (Acrylate/Vinylacetate adhesive) remainder
This composition was also subjected to a permeation test (mouse skin). The maximum flux was 5.3 µg/cm²/h. The permeation was 80 µg/cm²/24 h.

Claims

1. Transdermal drug delivery system (TDS) comprising
 - a cover which is impermeable for the active ingredient,
 - a matrix containing oxybutynin as active ingredient and
 - a facultative release liner, wherein the matrix further comprises
 - an Aloe Vera extract,
 - a pressure sensitive adhesive and
 - a cross linking agent for the adhesive.
2. Transdermal drug delivery system according to claim 1, comprising racemic oxybutynin, R-oxybutynin, S-oxybutynin or desethyl-oxybutynin.
3. Transdermal drug delivery system according to claim 1 or 2, wherein the pressure sensitive adhesive of the matrix comprises or consists of an acrylate based polymer, preferably a polymer based on an acrylate-vinyl acetate copolymer.
4. Transdermal drug delivery system according to any of the preceding claims, wherein the matrix comprises or consists of Durotak 2287 or Durotak 2516.
5. Transdermal drug delivery system according to any of the preceding claims, wherein the matrix comprises Ti-

acetylacetone, Al-acetylacetone or polybutyl-titanate as crosslinking agent.

6. Transdermal drug delivery system according to any of the preceding claims, wherein the extracting agent of the Aloe Vera-extract is a vegetable oil, preferably soybean oil.

7. Transdermal drug delivery system according to claim 6, wherein the Aloe Vera-extract comprises 5 to 15 % by weight of Aloe Vera oil and 95 to 85 % by weight of vegetable oil.

8. Transdermal drug delivery system according to any of the preceding claims, wherein the matrix comprises the Aloe Vera-extract as the only enhancer.

9. Transdermal drug delivery system according to any of the preceding claims, wherein the matrix comprises 5 to 40, preferably 10 to 35 and especially 15 to 30 % by weight of oxybutynin (based on the matrix).

10. Transdermal drug delivery system according to any of the preceding claims, wherein the matrix comprises 10 to 25, preferably 12 to 20 and especially 14 to 18 % by weight of Aloe Vera-extract (based on the matrix).

11. Transdermal drug delivery system according to any of the preceding claims, wherein the matrix comprises 0.1 to 5.0, preferably 0.3 to 3 and especially 0.5 to 2.0 % by weight of the crosslinking agent (based on the matrix).

12. Transdermal drug delivery system according to any of the preceding claims, wherein the system has a surface of 5 to 80, preferably 10 to 60 and especially 20 to 50 cm².

Summary

The invention concerns a transdermal drug delivery system (TDS) comprising

- a cover which is impermeable for the active ingredient,
- a matrix containing oxybutynin as active ingredient and
- a facultative release liner, wherein the matrix further comprises
 - an Aloe Vera extract,
 - a facultative skin care agent,
 - a pressure sensitive adhesive and
 - a cross linking agent for the adhesive.